CERIBELL INC (CBLL)
Health Care · Medical device diagnostics / neurological monitoring · NASDAQ
Ceribell develops wearable EEG systems and AI-powered software for rapid, automated seizure detection and brain monitoring in acute care settings.
What CERIBELL INC does
Ceribell Inc designs, manufactures, and sells the Ceribell System, a wearable EEG headband device combined with a portable recorder and cloud-based Clarity software platform for real-time seizure detection and brain activity monitoring. Founded in 2014 and commercially launched in 2018, the company targets acute care facilities including hospitals and intensive care units where rapid seizure detection is critical for patient outcomes. The Ceribell System received FDA 510(k) clearance for its recorder and headband in 2017 and for an early version of Clarity software in 2019, enabling the company to serve neurological monitoring applications in hospital settings.
Themes: ["Neurological monitoring / seizure detection","Wearable medical devices","AI-powered diagnostics","Acute care / hospital technology","Real-time patient monitoring"]
Fundamentals
- Price$19.64 as of 2026-07-09 close
- Market cap$745M as of 2026-07-10
- 1-year return+19.0% as of 2026-07-09 close
- Net margin-63.5% as of 2026-07-10
- Gross margin+87.7% as of 2026-07-10
- ROE-38.2% as of 2026-07-10
- Debt / equity0.14 as of 2026-07-10
- Revenue growth (YoY)+29.3% as of 2026-07-10
- Revenue CAGR (3y)+40.3% SEC XBRL
- Beta0.82 as of 2026-07-10
Key risks (from latest filing)
["Limited operating history (founded 2014, commercialized 2018) and rapid scaling challenges; company is unprofitable with -63.51% net margin and dependent on continued revenue growth to fund operations and product expansion.","Reimbursement and regulatory landscape changes; dependence on FDA approvals and third-party payer coverage decisions, with risks around pricing strategy modifications and evolving regulatory requirements for additional indications.","Manufacturing, supply chain, and operational scaling risks; company must expand manufacturing capabilities, recruit skilled personnel, and manage quality/compliance as it scales, with potential for cost overruns, production delays, or inability to meet demand."]
Competitors & peers
- Natus Medical (NTUS)
- Masimo (MASI)
- GE Healthcare (part of GE)
- Philips Healthcare (part of Philips)
- Nihon Kohden
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.